Jointly estimating epidemiological dynamics of Covid-19 from case and wastewater data in Aotearoa New Zealand.

BACKGROUND: Timely and informed public health responses to infectious diseases such as COVID-19 necessitate reliable information about infection dynamics. The case ascertainment rate (CAR), the proportion of infections that are reported as cases, is typically much less than one and varies with testing practices and behaviours, making reported cases unreliable as the sole source of data. The concentration of viral RNA in wastewater samples provides an alternate measure of infection prevalence that is not affected by clinical testing, healthcare-seeking behaviour or access to care. METHODS: We construct a state-space model with observed data of levels of SARS-CoV-2 in wastewater and reported case incidence and estimate the hidden states of the effective reproduction number, R, and CAR using sequential Monte Carlo methods. RESULTS: We analyse data from 1 January 2022 to 31 March 2023 from Aotearoa New Zealand. Our model estimates that R peaks at 2.76 (95% CrI 2.20, 3.83) around 18 February 2022 and the CAR peaks around 12 March 2022. We calculate that New Zealand's second Omicron wave in July 2022 is similar in size to the first, despite fewer reported cases. We estimate that the CAR in the BA.5 Omicron wave in July 2022 is approximately 50% lower than in the BA.1/BA.2 Omicron wave in March 2022. CONCLUSIONS: Estimating R, CAR, and cumulative number of infections provides useful information for planning public health responses and understanding the state of immunity in the population. This model is a useful disease surveillance tool, improving situational awareness of infectious disease dynamics in real-time.

To make informed public health decisions about infectious diseases, it is important to understand the number of infections in the community. Reported cases, however, underestimate the number of infections and the degree of underestimation likely changes with time. Wastewater data provides an alternative data source that does not depend on testing practices. Here, we combined wastewater observations of SARS-CoV-2 with reported cases to estimate the reproduction number (how quickly infections are increasing or decreasing) and the case ascertainment rate (the fraction of infections reported as cases). We apply the model to Aotearoa New Zealand and demonstrate that the second wave of infections in July 2022 had approximately the same number of infections as the first wave in March 2022 despite reported cases being 50% lower.

Steps towards operationalizing One Health approaches.

One Health recognizes the health of humans, agriculture, wildlife, and the environment are interrelated. The concept has been embraced by international health and environmental authorities such as WHO, WOAH, FAO, and UNEP, but One Health approaches have been more practiced by researchers than national or international authorities. To identify priorities for operationalizing One Health beyond research contexts, we conducted 41 semi-structured interviews with professionals across One Health sectors (public health, environment, agriculture, wildlife) and institutional contexts, who focus on national-scale and international applications. We identify important challenges, solutions, and priorities for delivering the One Health agenda through government action. Participants said One Health has made progress with motivating stakeholders to attempt One Health approaches, but achieving implementation needs more guidance (action plans for how to leverage or change current government infrastructure to accommodate cross-sector policy and strategic mission planning) and facilitation (behavioral change, dedicated personnel, new training model).

Ethical frameworks should be applied to computational modelling of infectious disease interventions.

This perspective is part of an international effort to improve epidemiological models with the goal of reducing the unintended consequences of infectious disease interventions. The scenarios in which models are applied often involve difficult trade-offs that are well recognised in public health ethics. Unless these trade-offs are explicitly accounted for, models risk overlooking contested ethical choices and values, leading to an increased risk of unintended consequences. We argue that such risks could be reduced if modellers were more aware of ethical frameworks and had the capacity to explicitly account for the relevant values in their models. We propose that public health ethics can provide a conceptual foundation for developing this capacity. After reviewing relevant concepts in public health and clinical ethics, we discuss examples from the COVID-19 pandemic to illustrate the current separation between public health ethics and infectious disease modelling. We conclude by describing practical steps to build the capacity for ethically aware modelling. Developing this capacity constitutes a critical step towards ethical practice in computational modelling of public health interventions, which will require collaboration with experts on public health ethics, decision support, behavioural interventions, and social determinants of health, as well as direct consultation with communities and policy makers.

The impact of Covid-19 vaccination in Aotearoa New Zealand: A modelling study.

Aotearoa New Zealand implemented a Covid-19 elimination strategy in 2020 and 2021, which enabled a large majority of the population to be vaccinated before being exposed to the virus. This strategy delivered one of the lowest pandemic mortality rates in the world. However, quantitative estimates of the population-level health benefits of vaccination are lacking. Here, we use a validated mathematical model of Covid-19 in New Zealand to investigate counterfactual scenarios with differing levels of vaccine coverage in different age and ethnicity groups. The model builds on earlier research by adding age- and time-dependent case ascertainment, the effect of antiviral medications, improved hospitalisation rate estimates, and the impact of relaxing control measures. The model was used for scenario analysis and policy advice for the New Zealand Government in 2022 and 2023. We compare the number of Covid-19 hospitalisations, deaths, and years of life lost in each counterfactual scenario to a baseline scenario that is fitted to epidemiological data between January 2022 and June 2023. Our results estimate that vaccines saved 6650 (95% credible interval [4424, 10180]) lives, and prevented 74500 [51000, 115400] years of life lost and 45100 [34400, 55600] hospitalisations during this 18-month period. Making the same comparison before the benefit of antiviral medications is accounted for, the estimated number of lives saved by vaccines increases to 7604 [5080, 11942]. Due to inequities in the vaccine rollout, vaccination rates among Maori were lower than in people of European ethnicity. Our results show that, if vaccination rates had been equitable, an estimated 11%-26% of the 292 Maori Covid-19 deaths that were recorded in this time period could have been prevented. We conclude that Covid-19 vaccination greatly reduced health burden in New Zealand and that equity needs to be a key focus of future vaccination programmes.

Near-term forecasting of Covid-19 cases and hospitalisations in Aotearoa New Zealand.

Near-term forecasting of infectious disease incidence and consequent demand for acute healthcare services can support capacity planning and public health responses. Despite well-developed scenario modelling to support the Covid-19 response, Aotearoa New Zealand lacks advanced infectious disease forecasting capacity. We develop a model using Aotearoa New Zealand's unique Covid-19 data streams to predict reported Covid-19 cases, hospital admissions and hospital occupancy. The method combines a semi-mechanistic model for disease transmission to predict cases with Gaussian process regression models to predict the fraction of reported cases that will require hospital treatment. We evaluate forecast performance against out-of-sample data over the period from 2 October 2022 to 23 July 2023. Our results show that forecast performance is reasonably good over a 1-3 week time horizon, although generally deteriorates as the time horizon is lengthened. The model has been operationalised to provide weekly national and regional forecasts in real-time. This study is an important step towards development of more sophisticated situational awareness and infectious disease forecasting tools in Aotearoa New Zealand.

Key Challenges for Respiratory Virus Surveillance while Transitioning out of Acute Phase of COVID-19 Pandemic.

To support the ongoing management of viral respiratory diseases while transitioning out of the acute phase of the COVID-19 pandemic, many countries are moving toward an integrated model of surveillance for SARS-CoV-2, influenza virus, and other respiratory pathogens. Although many surveillance approaches catalyzed by the COVID-19 pandemic provide novel epidemiologic insight, continuing them as implemented during the pandemic is unlikely to be feasible for nonemergency surveillance, and many have already been scaled back. Furthermore, given anticipated cocirculation of SARS-CoV-2 and influenza virus, surveillance activities in place before the pandemic require review and adjustment to ensure their ongoing value for public health. In this report, we highlight key challenges for the development of integrated models of surveillance. We discuss the relative strengths and limitations of different surveillance practices and studies as well as their contribution to epidemiologic assessment, forecasting, and public health decision-making.

Continued mitigation needed to minimise the high health burden from COVID-19 in Aotearoa New Zealand.

In this article we review the COVID-19 pandemic experience in Aotearoa New Zealand and consider the optimal ongoing response strategy. We note that this pandemic virus looks likely to result in future waves of infection that diminish in size over time, depending on such factors as viral evolution and population immunity. However, the burden of disease remains high with thousands of infections, hundreds of hospitalisations and tens of deaths each week, and an unknown burden of long-term illness (long COVID). Alongside this there is a considerable burden from other important respiratory illnesses, including influenza and RSV, that needs more attention. Given this impact and the associated health inequities, particularly for Maori and Pacific Peoples, we consider that an ongoing respiratory disease mitigation strategy is appropriate for New Zealand. As such, the previously described "vaccines plus" approach (involving vaccination and public health and social measures), should now be integrated with the surveillance and control of other important respiratory infections. Now is also a time for New Zealand to build on the lessons from the COVID-19 pandemic to enhance preparedness nationally and internationally. New Zealand's experience suggests elimination (or ideally exclusion) should be the default first choice for future pandemics of sufficient severity.

Modelling the impact of the Omicron BA.5 subvariant in New Zealand.

New Zealand experienced a wave of the Omicron variant of SARS-CoV-2 in early 2022, which occurred against a backdrop of high two-dose vaccination rates, ongoing roll-out of boosters and paediatric doses, and negligible levels of prior infection. New Omicron subvariants have subsequently emerged with a significant growth advantage over the previously dominant BA.2. We investigated a mathematical model that included waning of vaccine-derived and infection-derived immunity, as well as the impact of the BA.5 subvariant which began spreading in New Zealand in May 2022. The model was used to provide scenarios to the New Zealand Government with differing levels of BA.5 growth advantage, helping to inform policy response and healthcare system preparedness during the winter period. In all scenarios investigated, the projected peak in new infections during the BA.5 wave was smaller than in the first Omicron wave in March 2022. However, results indicated that the peak hospital occupancy was likely to be higher than in March 2022, primarily due to a shift in the age distribution of infections to older groups. We compare model results with subsequent epidemiological data and show that the model provided a good projection of cases, hospitalizations and deaths during the BA.5 wave.

Modelling Aotearoa New Zealand's COVID-19 protection framework and the transition away from the elimination strategy.

For the first 18 months of the COVID-19 pandemic, New Zealand used an elimination strategy to suppress community transmission of SARS-CoV-2 to zero or very low levels. In late 2021, high vaccine coverage enabled the country to transition away from the elimination strategy to a mitigation strategy. However, given negligible levels of immunity from prior infection, this required careful planning and an effective public health response to avoid uncontrolled outbreaks and unmanageable health impacts. Here, we develop an age-structured model for the Delta variant of SARS-CoV-2 including the effects of vaccination, case isolation, contact tracing, border controls and population-wide control measures. We use this model to investigate how epidemic trajectories may respond to different control strategies, and to explore trade-offs between restrictions in the community and restrictions at the border. We find that a low case tolerance strategy, with a quick change to stricter public health measures in response to increasing cases, reduced the health burden by a factor of three relative to a high tolerance strategy, but almost tripled the time spent in national lockdowns. Increasing the number of border arrivals was found to have a negligible effect on health burden once high vaccination rates were achieved and community transmission was widespread.

Using mechanistic model-based inference to understand and project epidemic dynamics with time-varying contact and vaccination rates.

Epidemiological models range in complexity from relatively simple statistical models that make minimal assumptions about the variables driving epidemic dynamics to more mechanistic models that include effects such as vaccine-derived and infection-derived immunity, population structure and heterogeneity. The former are often fitted to data in real-time and used for short-term forecasting, while the latter are more suitable for comparing longer-term scenarios under differing assumptions about control measures or other factors. Here, we present a mechanistic model of intermediate complexity that can be fitted to data in real-time but is also suitable for investigating longer-term dynamics. Our approach provides a bridge between primarily empirical approaches to forecasting and assumption-driven scenario models. The model was developed as a policy advice tool for New Zealand's 2021 outbreak of the Delta variant of SARS-CoV-2 and includes the effects of age structure, non-pharmaceutical interventions, and the ongoing vaccine rollout occurring during the time period studied. We use an approximate Bayesian computation approach to infer the time-varying transmission coefficient from real-time data on reported cases. We then compare projections of the model with future, out-of-sample data. We find that this approach produces a good fit with in-sample data and reasonable forward projections given the inherent limitations of predicting epidemic dynamics during periods of rapidly changing policy and behaviour. Results from the model helped inform the New Zealand Government's policy response throughout the outbreak.

Modelling the dynamics of infection, waning of immunity and re-infection with the Omicron variant of SARS-CoV-2 in Aotearoa New Zealand.

Aotearoa New Zealand experienced a wave of the Omicron variant of SARS-CoV-2 in 2022 with around 200 confirmed cases per 1000 people between January and May. Waning of infection-derived immunity means people become increasingly susceptible to re-infection with SARS-CoV-2 over time. We investigated a model that included waning of vaccine-derived and infection-derived immunity under scenarios representing different levels of behavioural change relative to the first Omicron wave. Because the durability of infection-derived immunity is a key uncertainty in epidemiological models, we investigated outcomes under different assumptions about the speed of waning. The model was used to provide scenarios to the New Zealand Government, helping to inform policy response and healthcare system preparedness ahead of the winter respiratory illness season. In all scenarios investigated, a second Omicron wave was projected to occur in the second half of 2022. The timing of the peak depended primarily on the speed of waning and was typically between August and November. The peak number of daily infections in the second Omicron wave was smaller than in the first Omicron wave. Peak hospital occupancy was also generally lower than in the first wave but was sensitive to the age distribution of infections. A scenario with increased contact rates in older groups had higher peak hospital occupancy than the first wave. Scenarios with relatively high transmission, whether a result of relaxation of control measures or voluntary behaviour change, did not necessarily lead to higher peaks. However, they generally resulted in more sustained healthcare demand (>250 hospital beds throughout the winter period). The estimated health burden of Covid-19 in the medium term is sensitive to the strength and durability of infection-derived and hybrid immunity against reinfection and severe illness, which are uncertain.

Real-time estimation of the effective reproduction number of SARS-CoV-2 in Aotearoa New Zealand.

During an epidemic, real-time estimation of the effective reproduction number supports decision makers to introduce timely and effective public health measures. We estimate the time-varying effective reproduction number, Rt , during Aotearoa New Zealand's August 2021 outbreak of the Delta variant of SARS-CoV-2, by fitting the publicly available EpiNow2 model to New Zealand case data. While we do not explicitly model non-pharmaceutical interventions or vaccination coverage, these two factors were the leading drivers of variation in transmission in this period and we describe how changes in these factors coincided with changes in Rt . Alert Level 4, New Zealand's most stringent restriction setting which includes stay-at-home measures, was initially effective at reducing the median Rt to 0.6 (90% CrI 0.4, 0.8) on 29 August 2021. As New Zealand eased certain restrictions and switched from an elimination strategy to a suppression strategy, Rt subsequently increased to a median 1.3 (1.2, 1.4). Increasing vaccination coverage along with regional restrictions were eventually sufficient to reduce Rt below 1. The outbreak peaked at an estimated 198 (172, 229) new infected cases on 10 November, after which cases declined until January 2022. We continue to update Rt estimates in real time as new case data become available to inform New Zealand's ongoing pandemic response.

Sensitivity of Reverse Transcription Polymerase Chain Reaction Tests for Severe Acute Respiratory Syndrome Coronavirus 2 Through Time.

BACKGROUND: Reverse transcription polymerase chain reaction (RT-PCR) tests are the gold standard for detecting recent infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Reverse transcription PCR sensitivity varies over the course of an individual's infection, related to changes in viral load. Differences in testing methods, and individual-level variables such as age, may also affect sensitivity. METHODS: Using data from New Zealand, we estimate the time-varying sensitivity of SARS-CoV-2 RT-PCR under varying temporal, biological, and demographic factors. RESULTS: Sensitivity peaks 4-5 days postinfection at 92.7% (91.4%-94.0%) and remains over 88% between 5 and 14 days postinfection. After the peak, sensitivity declined more rapidly in vaccinated cases compared with unvaccinated, females compared with males, those aged under 40 compared with over 40s, and Pacific peoples compared with other ethnicities. CONCLUSIONS: Reverse transcription PCR remains a sensitive technique and has been an effective tool in New Zealand's border and postborder measures to control coronavirus disease 2019. Our results inform model parameters and decisions concerning routine testing frequency.

Minimising the use of costly control measures in an epidemic elimination strategy: A simple mathematical model.

Countries such as New Zealand, Australia and Taiwan responded to the Covid-19 pandemic with an elimination strategy. This involves a combination of strict border controls with a rapid and effective response to eliminate border-related re-introductions. An important question for decision makers is, when there is a new re-introduction, what is the right threshold at which to implement strict control measures designed to reduce the effective reproduction number below 1. Since it is likely that there will be multiple re-introductions, responding at too low a threshold may mean repeatedly implementing controls unnecessarily for outbreaks that would self-eliminate even without control measures. On the other hand, waiting for too high a threshold to be reached creates a risk that controls will be needed for a longer period of time, or may completely fail to contain the outbreak. Here, we use a highly idealised branching process model of small border-related outbreaks to address this question. We identify important factors that affect the choice of threshold in order to minimise the expect time period for which control measures are in force. We find that the optimal threshold for introducing controls decreases with the effective reproduction number, and increases with overdispersion of the offspring distribution and with the effectiveness of control measures. Our results are not intended as a quantitative decision-making algorithm. However, they may help decision makers understand when a wait-and-see approach is likely to be preferable over an immediate response.

Modern Data Acquisition Approaches in Proteomics Based on Dynamic Instrument Control.

Traditionally, data acquisition in mass spectrometry-based proteomics is directed by user-defined parameters and relatively simple decision making, such as selection of the highest MS1 peaks for fragmentation. In recent years, access to two-way-communication with instrument codebases has led to a surge in algorithms instructing more complex decision processes on-the-fly. A closer matching between the time windows for monitoring peptides in targeted proteomics and their actual chromatographic elution peaks has been addressed through dynamic retention time scheduling and through triggered acquisition. Strategies based on real-time database searching and spectral matching have, among others, been used to adjust acquisition parameters for selected peptides for improved quantitative accuracy. While initial studies were mainly performed on a proof-of-concept level, dynamic acquisition approaches recently became more broadly available through software and increasing integration into standard instrument control and are likely to transform the field of proteomics in the coming years.

An assessment of the potential impact of the Omicron variant of SARS-CoV-2 in Aotearoa New Zealand.

New Zealand delayed the introduction of the Omicron variant of SARS-CoV-2 into the community by the continued use of strict border controls through to January 2022. This allowed time for vaccination rates to increase and the roll out of third doses of the vaccine (boosters) to begin. It also meant more data on the characteristics of Omicron became available prior to the first cases of community transmission. Here we present a mathematical model of an Omicron epidemic, incorporating the effects of the booster roll out and waning of vaccine-induced immunity, and based on estimates of vaccine effectiveness and disease severity from international data. The model considers differing levels of immunity against infection, severe illness and death, and ignores waning of infection-induced immunity. This model was used to provide an assessment of the potential impact of an Omicron wave in the New Zealand population, which helped inform government preparedness and response. At the time the modelling was carried out, the date of introduction of Omicron into the New Zealand community was unknown. We therefore simulated outbreaks with different start dates, as well as investigating different levels of booster uptake. We found that an outbreak starting on 1 February or 1 March led to a lower health burden than an outbreak starting on 1 January because of increased booster coverage, particularly in older age groups. We also found that outbreaks starting later in the year led to worse health outcomes than an outbreak starting on 1 March. This is because waning immunity in older groups started to outweigh the increased protection from higher booster coverage in younger groups. For an outbreak starting on 1 February and with high booster uptake, the number of occupied hospital beds in the model peaked between 800 and 3,300 depending on assumed transmission rates. We conclude that combining an accelerated booster programme with public health measures to flatten the curve are key to avoid overwhelming the healthcare system.

A stochastic mathematical model of 4D tumour spheroids with real-time fluorescent cell cycle labelling.

In vitro tumour spheroids have been used to study avascular tumour growth and drug design for over 50 years. Tumour spheroids exhibit heterogeneity within the growing population that is thought to be related to spatial and temporal differences in nutrient availability. The recent development of real-time fluorescent cell cycle imaging allows us to identify the position and cell cycle status of individual cells within the growing spheroid, giving rise to the notion of a four-dimensional (4D) tumour spheroid. We develop the first stochastic individual-based model (IBM) of a 4D tumour spheroid and show that IBM simulation data compares well with experimental data using a primary human melanoma cell line. The IBM provides quantitative information about nutrient availability within the spheroid, which is important because it is difficult to measure these data experimentally.

Potential reduction in transmission of COVID-19 by digital contact tracing systems: a modelling study.

BACKGROUND: Digital tools are being developed to support contact tracing as part of the global effort to control the spread of COVID-19. These include smartphone apps, Bluetooth-based proximity detection, location tracking and automatic exposure notification features. Evidence on the effectiveness of alternative approaches to digital contact tracing is so far limited. METHODS: We use an age-structured branching process model of the transmission of COVID-19 in different settings to estimate the potential of manual contact tracing and digital tracing systems to help control the epidemic. We investigate the effect of the uptake rate and proportion of contacts recorded by the digital system on key model outputs: the effective reproduction number, the mean outbreak size after 30 days and the probability of elimination. RESULTS: Effective manual contact tracing can reduce the effective reproduction number from 2.4 to around 1.5. The addition of a digital tracing system with a high uptake rate over 75% could further reduce the effective reproduction number to around 1.1. Fully automated digital tracing without manual contact tracing is predicted to be much less effective. CONCLUSIONS: For digital tracing systems to make a significant contribution to the control of COVID-19, they need be designed in close conjunction with public health agencies to support and complement manual contact tracing by trained professionals.

Species-range-size distributions: Integrating the effects of speciation, transformation, and extinction.

The species-range size distribution is a product of speciation, transformation of range-sizes, and extinction. Previous empirical studies showed that it has a left-skewed lognormal-like distribution. We developed a new mathematical framework to study species-range-size distributions, one in which allopatric speciation, transformation of range size, and the extinction process are explicitly integrated. The approach, which we call the gain-loss-allopatric speciation model, allows us to explore the effects of various speciation scenarios. Our model captures key dynamics thought to lead to known range-size distributions. We also fitted the model to empirical range-size distributions of birds, mammals, and beetles. Since geographic range dynamics are linked to speciation and extinction, our model provides predictions for the dynamics of species richness. When a species-range-size distribution initially evolves away from the range sizes at which the likelihood of speciation is low, it tends to cause diversification slowdown even in the absence of (bio)diversity dependence in speciation rate. Using the mathematical model developed here, we give a potential explanation for how observed range-size distributions emerge from range-size dynamics. Although the framework presented is minimalistic, it provides a starting point for examining hypotheses based on more complex mechanisms.

A COVID-19 vaccination model for Aotearoa New Zealand.

We develop a mathematical model to estimate the effect of New Zealand's vaccine rollout on the potential spread and health impacts of COVID-19. The main purpose of this study is to provide a basis for policy advice on border restrictions and control measures in response to outbreaks that may occur during the vaccination roll-out. The model can be used to estimate the theoretical population immunity threshold, which represents a point in the vaccine rollout at which border restrictions and other controls could be removed and only small, occasional outbreaks would take place. We find that, with a basic reproduction number of 6, approximately representing the Delta variant of SARS-CoV-2, and under baseline vaccine effectiveness assumptions, reaching the population immunity threshold would require close to 100% of the total population to be vaccinated. Since this coverage is not likely to be achievable in practice, relaxing controls completely would risk serious health impacts. However, the higher vaccine coverage is, the more collective protection the population has against adverse health outcomes from COVID-19, and the easier it will become to control outbreaks. There remains considerable uncertainty in model outputs, in part because of the potential for the evolution of new variants. If new variants arise that are more transmissible or vaccine resistant, an increase in vaccine coverage will be needed to provide the same level of protection.